Zymeworks is a biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Zymeworks Delaware Inc.
SEC CIK
Corporate docs
Subsidiaries
Zymeworks CallCo ULC • Zymeworks ExchangeCo Ltd. • Zymeworks BC Inc. • Zymeworks Management Inc. • Zymeworks Biopharmaceuticals Inc. • Zymeworks Pharmaceuticals Limited • Zymeworks Lifesciences Pte. Ltd. ...
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
2 Aug 24
424B5
Prospectus supplement for primary offering
2 Aug 24
8-K
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
1 Aug 24
10-Q
2024 Q2
Quarterly report
1 Aug 24
8-K
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
1 Aug 24
8-K
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
25 Jul 24
8-K
Other Events
10 Jun 24
8-K
Other Events
3 May 24
424B5
Prospectus supplement for primary offering
3 May 24
424B5
Prospectus supplement for primary offering
3 May 24
Transcripts
Earnings call transcript
2024 Q2
1 Aug 24
Earnings call transcript
2024 Q1
2 May 24
Earnings call transcript
2023 Q4
6 Mar 24
Earnings call transcript
2023 Q3
7 Nov 23
Earnings call transcript
2023 Q2
10 Aug 23
Earnings call transcript
2023 Q1
8 May 23
Earnings call transcript
2022 Q4
7 Mar 23
Earnings call transcript
2022 Q3
9 Nov 22
Latest ownership filings
144
Notice of proposed sale of securities
11 Jun 24
4
Neil Gallagher
2 Apr 24
3
Neil Gallagher
2 Apr 24
3
Scott Platshon
4 Mar 24
SC 13D
EcoR1 Capital, LLC
22 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
4
Alessandra Cesano
9 Feb 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.96 mm | 70.96 mm | 70.96 mm | 70.96 mm | 70.96 mm | 70.96 mm |
Cash burn (monthly) | 14.62 mm | 5.93 mm | 14.30 mm | 11.45 mm | 8.33 mm | 7.61 mm |
Cash used (since last report) | 25.90 mm | 10.50 mm | 25.33 mm | 20.28 mm | 14.76 mm | 13.49 mm |
Cash remaining | 45.06 mm | 60.46 mm | 45.63 mm | 50.68 mm | 56.20 mm | 57.47 mm |
Runway (months of cash) | 3.1 | 10.2 | 3.2 | 4.4 | 6.7 | 7.5 |
Institutional ownership, Q2 2024
99.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 160 |
Opened positions | 26 |
Closed positions | 31 |
Increased positions | 59 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 554.51 bn |
Total shares | 70.72 mm |
Total puts | 99.00 k |
Total calls | 54.70 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
EcoR1 Capital | 13.44 mm | $114.35 bn |
BVF | 5.87 mm | $49.95 bn |
Redmile | 5.21 mm | $44.35 bn |
MS Morgan Stanley | 4.24 mm | $36.08 bn |
BLK BlackRock | 4.19 mm | $35.69 bn |
Rubric Capital Management | 3.92 mm | $33.34 bn |
All Blue Falcons FZE | 2.79 mm | $24.39 mm |
Vanguard | 2.70 mm | $22.95 bn |
Deutsche Bank AG - Registered Shares | 2.36 mm | $20.07 bn |
BNP Paribas Asset Management Holding | 1.93 mm | $16.43 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Neil Gallagher | Stock Option Common Stock | Grant | Acquire A | No | No | 9.23 | 74,000 | 683.02 k | 74,000 |
8 Feb 24 | Alessandra Cesano | Stock Option Common Stock | Grant | Acquire A | No | No | 11.47 | 74,000 | 848.78 k | 74,000 |
News
Stifel Maintains Buy on Zymeworks, Raises Price Target to $21
2 Aug 24
Zymeworks Announces Share Repurchase Program Of Up To $60M Of Common Stock
1 Aug 24
Zymeworks Q2 2024 GAAP EPS $(0.49) Misses $0.07 Estimate, Sales $19.243M Miss $48.860M Estimate
1 Aug 24
Zymeworks Says FDA Has Cleared Investigational New Drug Application For ZW191
22 Jul 24
Market-Moving News for June 17th
17 Jun 24
Press releases
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
1 Aug 24
Zymeworks Announces Participation in Upcoming Investor Conferences
30 Jul 24
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
25 Jul 24
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
22 Jul 24
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
11 Jul 24